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Abstract	
The COVID-19 pandemic disrupted health care delivery of cancer screenings. The primary aim of
our work was to evaluate the degree to which populations were accepting of home-based screenings
for colorectal cancer (CRC) and cervical cancer (ie, primary human papillomavirus [HPV] testing).
Three groups of adults having distinct health burdens that may affect acceptance of home-based
cancer screening were identified through outpatient electronic medical records: those having survived
a COVID-19 hospitalization; those having been positive for a non-COVID-19 respiratory illness; or
those having type 2 diabetes. A total of 132 respondents (58% female) completed an online survey
with hypothetical cases about their acceptance of home-based CRC or cervical cancer screening.
Among women respondents, urine and vaginal screening for primary HPV testing was acceptable
to 64% and 59%, respectively. Among both men and women, at-home CRC screening with fecal
immunochemical test or Cologuard® was acceptable to 60% of the respondents. When adjusting for
education, women with a positive attitude toward home-based urine and vaginal screening were 49
times and 23 times more likely, respectively, to have a positive attitude toward CRC screening. These
findings indicate that home-based cancer screens for CRC and primary HPV testing are acceptable
to men and women and may allow for greater compliance with screening in the future. (J Patient Cent
Res Rev. 2021;8:340-346.)
Keywords	
home-based cancer screening; colorectal cancer; cervical cancer; human papillomavirus; HPV
screening

S

ARS-CoV-2 infections and the COVID-19
pandemic have caused global changes in health care
delivery, including a significant impact on outpatient
community-based primary care. Cancer screens requiring
in-office procedures decreased by more than 90% for
screenable cancers between March 19, 2020, and May
9, 2020,1,2 with the exception of the multitarget stool
DNA test (Cologuard®, Exact Sciences Corporation),
for which use only decreased by 65%. This suggests that
home-based colorectal cancer (CRC) screening was more
resilient to the effects of the pandemic and continued to
be acceptable to patients.
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Three groups of adults having distinct health burdens
could be expected to respond differently to cancer
screening invitations. Restricted access to primary care
during the pandemic has affected community-dwelling
adults needing management of chronic diseases such as
type 2 diabetes.3 Likewise, adults who have survived a
hospitalization for COVID-19 continue to have health
care needs while rehabilitating at home.4 Lastly, adults
with respiratory symptoms who tested positive for a nonCOVID-19 coronavirus or a rhinovirus and did not require
hospitalization still face similar restrictions in care access.5
For each of these groups of patients, participation in
traditional in-office cancer screening has been disrupted
by the pandemic. This situation may impact future
uptake of home-based cancer screening methods if
made available. CRC screening already has U.S. Food
and Drug Administration (FDA) approval for homebased testing options like stool DNA tests. Additionally,
the FDA is currently evaluating home-based cervical
cancer screening methods based on primary human
papillomavirus testing6,7 for approval in the United States.
COVID-19

The primary aim of this study was to explore, through
hypothetical cases, whether these three distinct cohorts
of outpatient adults would be willing to participate in
home-based screening for CRC and cervical cancer.

All adults were contacted by phone or email and invited
to participate in the survey after September 1, 2020. We
attempted contact up to 3 times and, for those agreeing, we
sent 1 follow-up reminder email to complete the survey.

METHODS

The study was determined to be exempt by the University
of Michigan institutional review board (HUM00182620).
Survey Development

The survey included sociodemographic questions
and hypothetical scenarios about home-based cancer
screening (Online Appendices A and B). The 3
scenarios involved home-based CRC screening using
a stool sample, home-based cervical cancer screening
using a urine sample, and home-based cervical cancer
screening using a vaginal swab sample. Details of
the test were not specified, and no other introductory
materials about the cancers or the screening tests were
provided. Responses ranged from not getting screened
at all, delaying screening until the in-office procedures
were available again, participating in the home-based
screening but only in the case that the office screenings
were not available, choosing to participate in the homebased screening regardless of whether or not the office
screenings were available, and unsure.
We piloted the survey in 10 adults for understanding,
sequencing order, and ease of answering. Qualtrics® XM
software (Qualtrics), a secure web-based application, was
used to support the survey data.
Population

Responses to cancer screening scenarios for 3 groups of
adults with differing health care needs were included.
Adults with the chronic disease type 2 diabetes whose
routine management was disrupted by the pandemic, adults
who survived a COVID-19 hospitalization, and adults
with an acute respiratory disease that was not COVID-19
were asked to participate. These 3 cohorts of adults were
identified through the electronic medical records of a
large Midwestern health system. Dates of hospitalization
were defined for the first wave of COVID-19 from
the beginning of 2020 through June 1, 2020. Cohort 1
included those with type 2 diabetes without respiratory
symptoms from January 1, 2020, through September 1,
2020. Cohort 2 included those with a positive respiratory
panel for a non-COVID-19 coronavirus (HKU1, 2229e,
NL63, or OC43) or a rhinovirus without hospitalization
from January 1, 2020, through September 1, 2020.
Cohort 3 included those that had survived a COVID-19
hospitalization and returned home between January 1,
2020, and May 31, 2020, thus allowing survivors at least
3 months at home for recovery.
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Table 1. Demographic Descriptors
Variable

Mean (SD)
or n (%)

Age in years, mean (SD)

56.3 (15.6)

Race, n (%)
White
Black
O
 ther (Hispanic, Asian, Alaska Native,
American Indian, MENA, Native
Hawaiian, Pacific Islander, multi-race)

93 (71.5%)
25 (19.2%)
12 (9.2%)

Gender, n (%)
Female
Male

76 (57.6%)
56 (42.4%)

Population cohort, n (%)
Diabetic – chronic illness
Acute respiratory – non-COVID-19
Survived hospitalization for COVID-19

50 (37.9%
41 (31.1%)
41 (31.1%)

Partner status, n (%)
Partnered
Single

87 (66.4%)
44 (33.6%)

Occupation, n (%)
Employed
Student
Unemployed
Retired/Disabled

45 (35.7%)
3 (2.4%)
20 (15.9%)
58 (46.0%)

Education, n (%)
High school or less
Some college
Completed college
Post college

18 (13.7%)
42 (32.1%)
39 (29.8%)
32 (24.4%)

Insurance, n (%)
Private
Public (Medicaid, Medicare, Tribal, other
state-sponsored)
None

75 (56.8%)
56 (42.4%)
1 (0.8%)

Length of time with PCP, n (%)
3 or fewer years
More than 3 years

47 (35.9%)
84 (64.1%)

Number in household, n (%)
2 or fewer persons
More than 2 persons

81 (62.8%)
48 (37.2%)

Tobacco use, n (%)
Current/Ever
Never

38 (29.0%)
93 (71.0%)

MENA, Middle East and North Africa; PCP, primary care
physician; SD, standard deviation.
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Statistical Analysis

In order to have the true proportion of acceptance of
home cancer screening be estimated within ±8 percentage
points with 95% confidence, when the true proportion
of acceptance is 70%, we needed a minimum of 132
respondents. Descriptive statistics produced frequencies,
and logistic regression analyses were performed to test
univariate predictors of home-based screening. All data
were analyzed with Statistica® software (version 13,
TIBCO Software Inc.).

RESULTS

Of the 879 people contacted, 132 (15%) completed the
survey; diabetics had the highest response rate of 27%
(50 of 183), followed by those with non-COVID-19
respiratory illnesses (16%, 41 of 259) and the COVID-19
hospital survivors (9%, 41 of 427). On average, the
diabetic group was the oldest, with mean age of 61
years (range: 23–79), followed by 58 years (31–77) for
those surviving COVID-19 hospitalization and 50 years
(18–94) for those with acute non-COVID-19 respiratory
illnesses. Table 1 shows that a majority of respondents
were White, female, partnered, retired/disabled, living
with no more than one other person, and had never
smoked. Most respondents (86.3%) had some college,
complete college, or postcollege education, and more
than half (56.8%) had private insurance versus 42.4%
on public plans. A majority also had a relationship with
their primary care physician for more than 3 years.
Table 2 shows the range of positive and negative response
categories for each home screening method. For homebased urine cervical cancer screening, 65% of women had
a positive attitude, 44 percentage points above those with
a negative attitude (P<0.001). Likewise, for home-based
vaginal cervical cancer screening, 59% of women had a
positive attitude, 32 percentage points above those with

a negative attitude (P<0.001). Additionally, for homebased fecal CRC screening, 60% of men and women had
a positive attitude, 37 percentage points above those with
a negative attitude (P<0.001).
Logistic regression modeling was used to predict those
with positive attitudes toward home-based cancer
screening (Table 3). Univariate modeling showed no
descriptive predictors of home vaginal- or urine-based
cervical cancer screening, including length of time with
the current primary care physician. Those with postcollege
education were 6.75 times more likely to have a positive
attitude toward home-based CRC screening (odds ratio
[OR]: 6.75, 95% CI: 1.37, 32.26) compared to those with
a high school or less education. In addition, we found
that having a positive attitude toward home-based CRC
screening significantly predicted those women who had
positive attitudes toward home-based urine (OR: 52 [95%
CI: 8, 327]) and vaginal (OR: 25 [95% CI: 5, 138]) cervical
cancer screens, by comparison to those with negative
attitudes. After adjusting for education, women with
positive attitudes toward home-based urine and vaginal
cervical cancer screening were more likely to screen with
home-based fecal CRC screening (adjusted OR of 48.7
[95% CI: 7, 336] and 23 [95% CI: 4, 142], respectively).
Table 4 presents the attitudinal frequencies by age and
gender for which the cancer screenings are recommended
by the U.S. Preventive Services Task Force and American
Cancer Society.8-10 For home-based CRC screening, 60%
of age-appropriate men and women affirmed this choice.
Likewise, for home-based cervical cancer screening, 72%
and 64% of age-appropriate women affirmed the urine
and vaginal methods, respectively. For women eligible
for both cancer screens, 64% indicated positive attitudes
toward home-based colorectal and cervical cancer
screening. While the age-appropriate-cancer-screen

Table 2. Frequency of Attitudes Toward Home-Based Screening
Urine cervical
cancer screening,
N=76
Attitude

Vaginal cervical
cancer screening,
N=76

Fecal colorectal
cancer screening,
N=132

n (%)

n (%)

n (%)

I would rather not get screened at all

8 (10.5%)

8 (10.5%)

9 (6.8%)

I would prefer to delay screening until I could
return to the office
Maybe

8 (10.5%)

13 (17.1%)

21 (15.9%)

11 (14.5%)

10 (13.2%)

23 (17.4%)

25 (32.9%)

25 (32.9%)

35 (26.5%)

24 (31.6%)

20 (26.3%)

44 (33.3%)

P<0.001

P<0.001

P<0.001

Yes, but only if the physician was not offering
in-office exams
Yes
Comparison of positive vs negative attitude
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Table 3. Predictors of Home-Based Cancer Screening
Urine cervical
cancer screening

Vaginal cervical
cancer screening

Fecal colorectal
cancer screening

OR

95% CI

OR

95% CI

OR

95% CI

Diabetic

4.25

0.69, 26.13

1.80

0.43, 7.53

2.37

0.87, 6.46

Respiratory

1.22

0.33, 4.60

1.20

0.34, 4.25

2.48

0.85, 7.24

Hospitalized

1.00

–

1.00

–

1.00

–

0.95

0.89, 1.01

0.98

0.90, 1.02

1.00

0.97, 1.03

Variable
Population group

Age
Race
White

1.00

–

1.00

–

1.00

–

Black

0.47

0.12, 1.92

0.89

0.23, 3.39

0.46

0.16, 1.29

Other

0.24

0.04, 1.37

0.30

0.06, 1.51

0.71

0.17, 3.04

Female

–

–

–

–

1.35

0.58, 3.16

Male

–

–

–

–

1.00

–

1.00

–

1.00

–

1.00

–

–

–

–

–

–

–

Gender

Occupation
Employed
Student
Unemployed

–

–

–

–

–

–

1.66

0.33, 4.12

0.89

0.27, 2.92

0.60

0.23, 1.61

High school or less

1.00

–

1.00

–

1.00

–

Some college

1.05

0.20, 5.60

0.82

0.16, 4.20

2.25

0.60, 8.48

Completed college

0.63

0.12, 8.94

0.38

0.07, 1.89

1.10

0.31, 3.91

Post college

3.19

0.44, 23.01

1.88

0.31, 11.52

6.75

1.37, 33.26

1 or 2

1.89

0.59, 6.07

1.61

0.55, 4.70

0.56

0.23, 1.34

More than 2

1.00

–

1.00

–

1.00

–

Ever/Current

0.79

0.21, 2.98

0.74

0.23, 2.39

1.68

0.68, 4.13

Never

1.00

–

1.00

–

1.00

–

Less than 3 years

1.00

–

1.00

–

1.00

–

3 years or more

0.57

0.18, 1.81

0.54

0.18, 1.59

0.41

0.17, 1.00

Private (employer or self-purchased)

1.00

–

1.00

–

1.00

–

Public (Medicaid, Medicare, Tribal, other
state-sponsored)

0.91

0.28, 2.95

0.84

0.29, 2.41

1.33

0.56, 3.18

52.50

8.40, 328.00

25.44

4.70, 137.77

–

–

Positive attitude toward home-based urine
cervical cancer screening after adjusting
for education

–

–

–

–

48.72*

7.05, 336.82

Positive attitude toward home-based vaginal
cervical cancer screening after adjusting
for education

–

–

–

–

23.23*

3.80, 141.84

Retired/Disabled
Education

Number in household

Tobacco use

Length of time with PCP

Insurance

Positive attitude toward home-based
colorectal cancer screening

*adjusted odds ratio.
OR, odds ratio; PCP, primary care physician.
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Table 4. Frequencies Limited to the Appropriate Age Ranges for Cancer Screenings
Recommended ages for
colorectal cancer
screening

Men:
45–75 years

Recommended
ages for primary
HPV screening

Intersecting age
ranges for both
screenings

N=34

N=25

N=30

Women:
45–75 years
N=43

0 (0%)

1 (2.3%)

–

0 (0%)

9 (30.0%)

7 (16.3%)

–

3 (12.0%)

3 (10.0%)
6 (20.0%)

9 (20.9%)
11 (25.6%)

–
–

6 (24.0%)
6 (24.0%)

12 (40.0%)

15 (34.9%)

–

10 (40.0%)

I would rather not get screened at all
I would prefer to delay screening until I
could screen in the office
Maybe
Yes, but only if the physician was not
offering in-office exams
Yes

–
–

–
–

0 (0%)
3 (8.8%)

0 (0%)
3 (12.0%)

–
–

–
–

4 (11.8%)
12 (35.3%)

4 (16.0%)
7 (28.0%)

–

–

15 (44.1%)

11 (44.0%)

Vaginal HPV testing, n (%)

–

–

I would rather not get screened at all

–

–

1 (2.9%)

1 (4.0%)

I would prefer to delay screening until I
could screen in the office
Maybe
Yes, but only if the physician was not
offering in-office exams
Yes

–

–

3 (8.8%)

3 (12.0%)

–
–

–
–

5 (14.7%)
16 (38.2%)

5 (20.0%)
7 (28.0%)

–

–

12 (35.3%)

9 (36.0%)

Screening test

Women:
25–65 years

Women:
45–65 years

Stool colorectal cancer testing, n (%)
I would rather not get screened at all
I would prefer to delay screening until I
could screen in the office
Maybe
Yes, but only if the physician was not
offering in-office exams
Yes
Urine HPV testing, n (%)

HPV, human papillomavirus.

sample sizes were small, the frequencies were similar to
that of the entire study population, which was powered to
see differences in acceptance.

DISCUSSION

This pilot work revealed that, in the first year of the
COVID-19 pandemic, adults with health care needs
generally had positive attitudes toward home-based cancer
screenings. Despite expecting people with diabetes, who
may be used to home glucose testing and monitoring
diet/exercise, to have greater acceptance of home-based
screening, the majority of respondents in each study
cohort had a positive response to at-home cancer screening
scenarios. To date, very little work has focused on both
home-based colorectal and cervical cancer screenings.
We find it appropriate to link these two at-home screens
together, as for women, they could be efficiently
accomplished with a single at-home bathroom experience.
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Our study showed that traditional barriers to screening,11
such as less education, male gender, non-White race, and
occupational status, did not affect the positive attitudes
for at-home cancer screening. In addition, our data did not
indicate that a long-term physician relationship affected
attitudes toward home-based cancer screening, a factor
previous shown to be important for adherence to other
cancer screenings.12-14 Instead, we found that adults have
a positive attitude toward home-based screening when
given an option, even during an infectious pandemic with
restrictive access to health care.
Our study does have limitations. While the response
rate in each of the three patient groups was too small for
generalizability, the overall data did appear to show that
acceptability of home-based cancer screening was above
the 2020 Centers for Disease Control and Preventionreported fecal occult blood test/fecal immunochemical

COVID-19

test rates.15 In addition, this was a cross-sectional
study of hypothetical screening scenarios without full
cancer screening education or input from respondents’
primary care physicians. Lastly, the confidence intervals
surrounding the odds ratios predicting home-based
screening acceptance were very large, requiring a much
larger future survey sample to confirm results.
While the COVID-19 pandemic has accelerated the
use of video and phone visits to facilitate the delivery
of health care,15,16 the movement to encourage homebased cancer screening has yet to increase. This pilot
study found that adults have positive attitudes about
home-based cancer screens, which could have multiple
benefits for those who face barriers to office-based
services (such as transportation, hours of accessibility,
and poor past experiences with sexual abuse or other
invasive medical exams). Home-based cancer screening
may complement and expand the shift to the virtual
delivery of health care, bringing tests to the homes of
patients.

Patient-Friendly Recap
• As more health care shifts to virtual, at-home
models, new approaches to cancer screening may
prove beneficial.
• Authors surveyed 132 adults who had 1 of 3
limitations to receiving in-office cancer screening
during the pandemic in order to gauge patients’
attitudes toward completing home-based cervical or
colorectal screens.
• A majority of female respondents reported that the
at-home urine and vaginal HPV tests would be
acceptable. Similarly, 60% of all respondents (men
and women) approved of home-based colorectal
cancer testing.
•H
 ome-based cancer screening may improve
compliance with recommended preventive care.
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